The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Noom will offer its version of compounded semaglutide - the active ingredient in Wegovy and diabetes drug Ozempic - as part ... U.S. Food and Drug Administration regulations.

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight ... dosages slightly different from the standard, FDA-approved amounts or including additives such as vitamins ...